Skip to main content
Equibles
STE logo

STE · STERIS plc · Documents

Track STE — free

Use STE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research STE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$253.44 -2.83 (-1.10%) At close · Nov 12 Play latest call Q1 2027 earnings call transcript
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$24.61B
Shares
97.11M
Volume · Nov 12 517.64K Avg daily vol (3M) 707.12K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2026 Revenue $5.94B up 8.7% 10-K filed May 29, 2026 Quarterly report FY2027 Q2 Revenue $1.59B up 8.8% 10-Q filed Nov 5, 2026 Latest results Revenue rises 9%; adjusted EPS outlook raised to $11.35 to $11.55 8-K filed Nov 4, 2026 Earnings call Q1 2027 earnings call Held Aug 6, 2026
2026
Nov 12
Current report 8-K Events of Nov 9
Other events AI summary on its way
Nov 6
Registration statement S-3ASR
Registers flexible shelf for debt and equity offerings

STERIS plc and certain subsidiaries registered a shelf for debt securities, guarantees, ordinary and preferred shares, warrants, and units, to be sold in future offerings. Net proceeds are expected for general corporate purposes, with final terms set in prospectus supplements.

Read from the first part of this long document
3 source passages
STERIS plc or any of its subsidiaries listed above may from time to time offer and sell any of the securities identified above, or any combination thereof, in each case, in one or more series and in one or more offerings. STERIS plc or any of its subsidiaries listed above will provide the specific terms of the securities to be offered in one or more supplements to this prospectus. Unless we inform you otherwise in the applicable prospectus supplement, we expect to use the net proceeds from the sale of our securities to which this prospectus relates for general corporate purposes. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2027 Q2, ended Sep 30
Xodus Medical acquisition valued at $2.1 billion

STERIS agreed to acquire Xodus Medical for approximately $2.1 billion in cash at closing, plus potential earnout consideration of up to $150.0 million, and expects to close by December 31, 2026.

Revenue $1.59B ▲ 8.8% Net income $213.7M ▲ 11.4%
Read from the MD&A section
Source passage
On October 11, 2026, we entered into the Purchase Agreement to acquire Xodus Medical for approximately $2.1 billion in cash at closing, subject to customary adjustments, plus potential earnout consideration of up to $150.0 million. We expect to close the Xodus Medical Acquisition by December 31, 2026, subject to customary closing conditions and regulatory approvals. Open the document at this passage
Nov 4
Current report 8-K
$1,600 million revolver and $500 million acquisition loan

On November 4, 2026, STERIS plc entered a $1,600 million revolving credit facility, replacing the October 7, 2024 agreement, and arranged up to $500 million of delayed-draw term financing contingent on the Xodus Medical, Inc. acquisition closing.

Entered into a material agreement, Ended a material agreement, New debt or off-balance-sheet obligation Read from the first part of this long document
3 source passages
On November 4, 2026, STERIS plc (“STERIS”), STERIS Corporation (“Corporation”), STERIS Limited (“Limited”) and STERIS Irish FinCo Unlimited Company (“FinCo”), each as a borrower and guarantor, entered into a credit agreement (the “New Revolving Credit Agreement”) with various financial institutions and each of J.P. Morgan SE and JPMorgan Chase Bank, N.A., as administrative agents, providing for a $1,600 million revolving credit facility (the “Revolver”), which replaces the existing credit agreement, dated as of October 7, 2024 (the “Existing Revolving Credit Agreement”). On November 4, 2026, FinCo, as borrower, and each of STERIS, Corporation and Limited, as guarantors, entered into a new delayed draw term loan credit agreement (the “Delayed Draw Term Loan Agreement”) with various financial institutions and J.P. Morgan SE, as administrative agent, which provides for a delayed draw term loan facility in the amount of up to $500 million (the “Delayed Draw Term Loan”). The Delayed Draw Term Loan cannot be utilized unless, among other conditions, the acquisition of Xodus Medical, Inc. (the “Xodus Medical Acquisition”) is consummated, and the commitments under such Delayed Draw Term Loan will terminate if the Xodus Medical Acquisition is validly terminated or the specified outside date occurs, among other customary conditions. Open the document at this passage
Nov 4
Current report 8-K
Revenue rises 9%; adjusted EPS outlook raised to $11.35 to $11.55

STERIS plc reported fiscal 2027 second-quarter revenue growth of 9% and diluted EPS of $2.19 for the quarter ended September 30, 2026, while raising its fiscal 2027 adjusted diluted EPS outlook to $11.35 to $11.55.

Financial results, Exit or restructuring costs
4 source passages
Fiscal 2027 second quarter revenue increased 9%; constant currency organic revenue growth was 8% Fiscal 2027 second quarter as reported diluted EPS increased to $2.19; adjusted EPS per diluted share increased to $2.94 DUBLIN, IRELAND - (November 4, 2026) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 second quarter ended September 30, 2026. Adjusted earnings per diluted share are now anticipated to be in the range of $11.35 to $11.55, an increase from prior expectations of $11.10 to $11.30. Open the document at this passage
Oct 13
Current report 8-K Events of Oct 11
Entered into a material agreement

STERIS plc agreed to acquire Xodus Medical, Inc. for $2.1 billion cash at closing, plus potential earnout consideration of up to $150 million tied to calendar 2028 performance targets. Closing is anticipated by December 31, 2026, subject to regulatory approvals.

Aug 7
Quarterly report 10-Q FY2027 Q1, ended Jun 30
Quarterly report for FY2027 Q1 AI summary on its way
Revenue $1.49B ▲ 7.3% Net income $200.1M ▲ 12.8%
Jun 11
Proxy statement DEF 14A Meeting Jul 31, 2026
Proxy statement AI summary on its way
May 29
Annual report 10-K FY2026, ended Mar 31
Annual report for FY2026 AI summary on its way
Revenue $5.94B ▲ 8.7% Net income $782.3M ▲ 27.3% Diluted EPS $7.93 ▲ 27.9%
Feb 6
Quarterly report 10-Q FY2026 Q3, ended Dec 31
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $1.5B ▲ 9.2% Net income $192.9M ▲ 11.2% Diluted EPS $1.96 ▲ 12.0%
2025
Nov 6
Quarterly report 10-Q FY2026 Q2, ended Sep 30
Quarterly report for FY2026 Q2
Revenue $1.46B ▲ 9.9% Net income $191.9M ▲ 27.9% Diluted EPS $1.94 ▲ 28.5%
Aug 7
Quarterly report 10-Q FY2026 Q1, ended Jun 30
Quarterly report for FY2026 Q1
Revenue $1.39B ▲ 8.7% Net income $177.4M ▲ 22.0% Diluted EPS $1.79 ▲ 22.6%
May 29
Annual report 10-K FY2025, ended Mar 31
Annual report for FY2025
Revenue $5.46B ▲ 6.2% Net income $614.64M ▲ 62.5% Diluted EPS $6.20 ▲ 62.7%
Feb 7
Quarterly report 10-Q FY2025 Q3, ended Dec 31
Quarterly report for FY2025 Q3
Revenue $1.37B ▲ 5.6% Net income $173.53M ▲ 23.3% Diluted EPS $1.75 ▲ 23.2%
2024
Nov 7
Quarterly report 10-Q FY2025 Q2, ended Sep 30
Quarterly report for FY2025 Q2
Revenue $1.33B ▲ 7.3% Net income $150.03M ▲ 30.1% Diluted EPS $1.51 ▲ 30.2%
Aug 8
Quarterly report 10-Q FY2025 Q1, ended Jun 30
Quarterly report for FY2025 Q1
Revenue $1.28B ▲ 8.1% Net income $145.4M ▲ 17.7% Diluted EPS $1.46 ▲ 16.8%
Showing 1–50 of 140 documents
Key facts CIK 1757898 CUSIP G8473T100 13F (30d) 588 filings 551 filers Visit website Investor relations